The human apical sodium-dependent bile acid transporter (ASBT; SLC10A2) is an important mechanism for intestinal bile acid reabsorption and plays a critical role in bile acid and cholesterol homeostasis. Its physiological role impacts human health and disease. Furthermore, it is a potential candidate for prodrug targeting due to its high transporter capacity and efficiency. However, the understanding of ASBT’s structural determinate of binding and translocation is limited. The work in this dissertation was carried out to study the inhibition and substrate requirement of ASBT, and subsequently to optimize the inhibition assay condition. In particular, work aimed to (1) identify FDA-approved drugs that inhibit ASBT and to derive computational models for ASBT inhibition; (2) evaluate the structural requirements of ASBT by 3D-QSAR analysis using aminopyridine and aminophenol conjugates of chenodeoxycholic acid; (3) synthesis and evaluate in vitro the potential of prolonged release prodrugs via targeting ASBT; (4) identify inhibitor concentrations to efficiently screen and measure inhibition constant K i values against solute carrier transporters; (5) assess compound cytotoxicity on in vitro apparent transporter inhibition.
Many FDA-approved drugs from diverse classes, such as the dihydropyridine calcium channel blockers and HMG CoA-reductase inhibitors were found to be ASBT inhibitors. A 3D-QSAR and a Bayesian model were developed using 38 molecules. 3D-QSAR models also were developed using C-24 conjugates. The models concluded that steric and hydrophobic features strongly influenced conjugate interaction with ASBT, and that the relative location of the pyridine nitrogen and substituent groups also modulated binding. Similar values for K i and Kt indicated that substrate binding to ASBT was the rate-limiting step. In vitro results showed that the bile acid conjugates are potential prolonged release prodrugs with binding affinity for ASBT. Experimental conditions for K i screening are suggested to use 10-fold the substrate affinity Kt for potent inhibitors and 100-fold K t for nonpotent inhibitors; for Ki measurement, the inhibitor concentration range should use 0 to estimated K i via five different inhibitor concentrations, where a low range of inhibitor concentrations can be used. For some drugs, their cytotoxicites contributed to or were associated with apparent transporter inhibition, where cytotoxicity differed between MDCK and HEK cells; cytotoxicity is suggested for future studies. Overall, the work carried out in this dissertation will aid in advancement in future prodrug design that exploits ASBT and made recommendations for the efficiency and quality of transporter inhibition assays in general.
|Advisor:||Polli, James E.|
|Commitee:||Ekins, Sean, Shu, Yan, Swaan, Peter W., Wang, Hongbing|
|School:||University of Maryland, Baltimore|
|School Location:||United States -- Maryland|
|Source:||DAI-B 71/06, Dissertation Abstracts International|
|Keywords:||Apical sodium-dependent bile acid transporter, Bile acid transporters, Cell culture, Cytoxicity, Prodrugs|
Copyright in each Dissertation and Thesis is retained by the author. All Rights Reserved
The supplemental file or files you are about to download were provided to ProQuest by the author as part of a
dissertation or thesis. The supplemental files are provided "AS IS" without warranty. ProQuest is not responsible for the
content, format or impact on the supplemental file(s) on our system. in some cases, the file type may be unknown or
may be a .exe file. We recommend caution as you open such files.
Copyright of the original materials contained in the supplemental file is retained by the author and your access to the
supplemental files is subject to the ProQuest Terms and Conditions of use.
Depending on the size of the file(s) you are downloading, the system may take some time to download them. Please be